Highest-materiality recent filing
Evolus Q1 2026 rev $73.1M (+7% YoY); Adjusted EBITDA positive $0.6M
Global net revenue $73.1M (+7% vs Q1 2025); GAAP operating loss narrowed to $6.8M from $15.2M.
Evolus Q4 GAAP operating income $4.2M; FY25 revenue $297.2M up 12%; guides 2026 rev $327-337M
Q4 GAAP operating income $4.2M vs loss $2.3M YoY; Non-GAAP operating income $7.1M, above guidance.
Evolus Q4 2025 prelim rev $88.6-90.6M (+12-15%); 2026 rev guide $327-337M; targets profitability
Preliminary Q4 2025 net revenue $88.6M-$90.6M, 12-15% YoY growth; positive non-GAAP op income $5M-$7M.
Evolus Q3 revenue $69M (+13% YoY); expects Q4 non-GAAP operating profit $5-7M
Q3 total net revenue $69.0M, up 13% YoY; global Jeuveau $63.2M, Evolysse $5.7M.
Q2 net revenue $69.4M, up 4% YoY; GAAP op loss $10.2M vs $7.7M loss YoY; non-GAAP op loss $7.9M vs $1.1M income.
Evolus CFO Sandra Beaver resigns effective June 13, 2025, to join private mental health tech company
Sandra Beaver resigns as CFO effective June 13, 2025; no disagreement with the company on operations or accounting.
Simone Blank voluntarily stepped down from the board of directors of the Company (the “Board”) effective on June 5, 2025, as part of a planned board refreshment and transition.
On May 27, 2025, Evolus, Inc. (the “Company”) announced that Sandra Beaver had informed the Company of her decision to voluntarily resign from her position as the Chief Financial Officer, effective as of June 13, 2025, to pursue another opportunity.
Max materiality 0.80 · Median 0.70 · Most common event earnings